ENहिन्दी soon
Home/India/Answers/Is Ozempic safe?
INIndia Side effects and safety

Is Ozempic safe?

GLP Guidebook teamUpdated 5 Oct 202616 sourcesWritten from published sources
The short answer

Ozempic (semaglutide) is approved for type 2 diabetes in the US, EU and India. Up to 20 in 100 feel sick, vs 6 on a dummy (US label). The EU label rates pancreatitis uncommon (under 1 in 100). The US label's boxed warning bars anyone with medullary thyroid cancer or a family history of it.

Before you go further
  • GLP‑1 medicines are prescription-only in India, not sold over the counter.11
  • A government statement on 1 Apr 2026 said only endocrinologists, internal-medicine specialists and cardiologists can prescribe them.11 CDSCO expert-committee minutes attach a similar condition to some approvals (endocrinologist or internal-medicine specialist). We found no rule covering every brand.12,13
  • What a prescription involves is in Guide 6: Seeing a doctor, and the medicines in India.
  • Nothing here says Ozempic is right for any one person.

Who has approved Ozempic, and on what evidence?

The US, the EU and India have approved Ozempic (semaglutide) for adults with type 2 diabetes; the US and EU labels rest on large trials.2,3,4,5

The US FDA approved it on 5 Dec 2017, and the EU on 8 Feb 2018.3,4 India's drug regulator, CDSCO, approved it for adults with poorly controlled type 2 diabetes, alongside diet and exercise.5 ANI reported this on 30 Sep 2025; Ozempic launched here in Dec 2025.5,6

The EU label's safety data cover 4,792 people on Ozempic in 8 late-stage trials.2 In India, Ozempic is the diabetes brand; Wegovy is the weight brand.7 See Wegovy vs Ozempic.

Which side effects are common, and which are serious?

Nausea is very common (over 1 in 10), mostly while the dose rises; in the EU label, pancreatitis is uncommon and gallstones common.1,2

Per 100 peopleOzempic 0.5 mgOzempic 1 mgDummy injection
Feeling sick (nausea)16206
Vomiting592
Diarrhoea992
Stopped because of stomach effects34under 1

US label, not the Indian one: 2 trials, 521 people on Ozempic, about 33 weeks.1

More in Ozempic side effects. The EU label rates a swollen pancreas (pancreatitis) uncommon: 1 in 100 to 1 in 1,000.2 US-label trials found 0.3 cases a year for every 100 people on it, vs 0.2 on other drugs.1 Gallstones are common (1 in 10 to 1 in 100): 1.5% on 0.5 mg, vs none on the dummy.1,2 In the EU label, severe low blood sugar (a hypo) came mainly with insulin (1.5%) or a sulfonylurea (1.2%).2 Sulfonylureas are older diabetes pills such as glimepiride. See pancreatitis and gallbladder problems.

Get help now: call 112 for severe stomach pain that won't go away. It may spread to your back, with or without vomiting.1,16 See a doctor at once for sudden sight loss or fast-worsening eyesight.2

Who must not use Ozempic?

The US label rules out anyone with a serious allergy to it, or with medullary thyroid cancer (MTC) in themselves or their family.1

It also rules out MEN 2, an inherited gland condition.1 The EU label says it should not be used in pregnancy or breastfeeding, and is no substitute for insulin.2 Both labels say to stop it at least 2 months before a planned pregnancy.1,2 See pregnancy and the pill. Safety in children has not been established.1 See Guide 4: Should I consider a GLP‑1?

The WHO has reported fake semaglutide worldwide since 2022, some containing insulin.14 See how to spot a fake pen in India.

Take your safety questions to the appointment

Build a list of questions to ask. Free, no sign-up.

Make my list

What do long-term trials show, and what is still unknown?

Two trials of 2 to about 3 years found fewer heart events on semaglutide, but more people stopped over side effects or other health problems.8,9

SUSTAIN-6 followed 3,297 people with type 2 diabetes for 104 weeks.8 A heart attack, stroke or heart death hit 6.6% vs 8.9%.8 Diabetic eye complications, common in the EU label, hit 3.0% vs 1.8%.1,2 SELECT used Wegovy's higher 2.4 mg dose in 17,604 people without diabetes.9 Over about 40 months, 16.6% stopped because of them, vs 8.2% on the dummy.9

The US label’s boxed (strongest) warning is about thyroid tumours. Rodents given semaglutide grew them; whether this happens in people is unknown.1 See the thyroid cancer warning. A 1,500-person eye trial is due to finish in Nov 2027.10 The EU label rates sudden sight loss in one eye (NAION) very rare. That is about 1 extra case a year for every 10,000 people on it.2 In Apr 2026, India's drug-safety programme said it monitors GLP‑1 side-effect reports.15

RisksThe risks, in brief
  • Nausea, very common. 20% on 1 mg vs 6% on a dummy injection.1
  • Pancreatitis, uncommon. 0.3 cases a year per 100 people; severe stomach pain, sometimes to the back.1,2
  • Gallstones, common. 1.5% on 0.5 mg vs none on a dummy.1,2
  • Eye complications in people with diabetic eye disease: 8.2% vs 5.2%.1
  • Thyroid. Tumours in rodents; the US label rules it out with a personal or family history of MTC, or MEN 2.1
  • Severe hypos with a sulfonylurea (1.2%) or insulin (1.5%).2
Full detail in Guide 5: Side effects and risks →

Read the full picture

Related questions

Is Ozempic available in India? Is semaglutide the same as Ozempic? How long does Ozempic take to work? Can you take Ozempic if you don't have diabetes? Do you need a prescription for GLP-1 medicines in India?
Did this answer your question?

Sources

  1. Novo Nordisk. Ozempic (semaglutide) injection, US prescribing information and Medication Guide, revised 05/2026. US label, not the Indian one: we found no public Indian label. Boxed warning; sections 1, 4, 5.2, 5.3, 5.5–5.9, 6.1 (Table 1), 8.3, 8.4. novo-pi.com
  2. European Medicines Agency. Ozempic: EU product information (summary of product characteristics), sections 4.4, 4.6, 4.8. EU label. ema.europa.eu
  3. US FDA. NDA 209637 approval letter, Ozempic (semaglutide) injection, 5 Dec 2017 (Drugs@FDA). accessdata.fda.gov
  4. European Medicines Agency. Ozempic: EPAR overview. Marketing authorisation issued 8 Feb 2018. ema.europa.eu
  5. ANI (Shalini Bhardwaj). CDSCO approves Danish drugmaker Novo Nordisk's injection for Type 2 diabetes patients, 30 Sep 2025. Quotes the approval wording. aninews.in
  6. Business Standard. Novo Nordisk launches Ozempic in India, 12 Dec 2025. business-standard.com
  7. Business Standard (Sanket Koul). Novo Nordisk cuts Ozempic, Wegovy prices by up to 48% in India, 31 Mar 2026. business-standard.com
  8. Marso SP et al. Semaglutide and cardiovascular outcomes in patients with type 2 diabetes (SUSTAIN-6). N Engl J Med 2016;375:1834–44. Funded by Novo Nordisk. doi:10.1056/NEJMoa1607141 · PMID 27633186
  9. Lincoff AM et al. Semaglutide and cardiovascular outcomes in obesity without diabetes (SELECT). N Engl J Med 2023;389:2221–32. Funded by Novo Nordisk. doi:10.1056/NEJMoa2307563 · PMID 37952131
  10. ClinicalTrials.gov. NCT03811561 (FOCUS): semaglutide vs placebo and diabetic eye disease. Active, not recruiting; primary completion estimated 7 Nov 2027. clinicaltrials.gov
  11. PIB Research. GLP-1 drugs: use, risks, and regulation. Government backgrounder, 1 Apr 2026. static.pib.gov.in
  12. CDSCO. Recommendations of the SEC (Endocrinology & Metabolism), 20–21 Apr 2023, item 1 (tirzepatide). cdsco.gov.in · archived copy
  13. CDSCO. Recommendations of the SEC (Endocrinology & Metabolism), 13–14 Feb 2024, items 3–4 (semaglutide). cdsco.gov.in · archived copy
  14. WHO. WHO issues warning on falsified medicines used for diabetes treatment and weight loss, 20 Jun 2024. who.int
  15. VOH Network. Indian Pharmacopoeia Commission to monitor safety of GLP-1 weight loss drugs, 6 Apr 2026. vohnetwork.com
  16. NIMSME (Ministry of MSME). Dial 112: an Emergency Response Support System (ERSS), 19 Feb 2019. nimsme.gov.in

Last checked 5 Oct 2026 · Next review due 5 Oct 2027 · Report an error

How this answer was made. Written by the GLP Guidebook team from the sources above. It's general information, not medical advice. Talk to a qualified doctor before starting, stopping or changing any medicine. How we write